Post by
rgonlyfactspls on Nov 23, 2014 10:54pm
Recent article (Nov 10-14) with helpful table...
Listing drugs and biologics in clinical testing for bladder cancer. - "Bladder Cancer: New Drugs in the Pipeline & the Role of Biomarkers"; Source: Thompson Reuters. Note: MCNA listed as "Regressin" under "Drug name". Disappointing to see incorrect name but focus on the bigger picture of lack of competition. And, in case you are not aware of the setbacks for Spectrum's Apaziquone see two links below (TheStreet provides the colour commentary). And, note: Apaziquone is not a direct competitor to MCNA as targeting the adjuvant setting i.e., post resection, and for low risk NMI bladder tumours. Links to publications mentioned: https://lsconnect.thomsonreuters.com/bladder-cancer-new-drugs-pipeline-role-biomarkers/ --- https://www.thestreet.com/story/11828564/1/spectrum-pharmas-bladder-cancer-bamboozle.html --- https://www.sppirx.com/321-spectrum-products-late-stage-apaziquone.html
Comment by
majimoto on Nov 28, 2014 12:06am
The Roche drug listed in the Thomson Reuters table was hyped in a recent BBC Health news article: https://www.bbc.com/news/health-30206539 MPDL-3280A MPDL-3280A MPDL-3280A